Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
Axsome Therapeutics, Inc. is experiencing a surge in prescriptions for its drug AUVELITY, particularly for Alzheimer's disease agitation, as the indication gains traction. Weekly new-to-brand prescriptions for AUVELITY reached a record 3,800, with the Alzheimer's disease agitation segment becoming the fastest-growing area. Patients aged 65 and older now account for approximately 31% of new-to-brand prescriptions, up from around 19% before the indication's approval.
The company expects operating expenses to remain stable while revenue grows faster, aiming for profitability. Axsome has also expanded its commercial organization and currently has first-line or first-switch access in most plans. Management expects revenue growth to outpace expense growth, supporting a path to profitability. The company has reiterated its $8 billion long-term peak-sales outlook for AUVELITY, with equal potential sales between major depressive disorder and Alzheimer's disease agitation.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
